1Simon G,Ginsberg RJ,Ruckdeschel JC. Small-cell lung cancer[J].Chest Surgery Clinics of North America,2001.165-188.
2Simon M,Argiris A,Murren JR. Progress in the therapy of small cell lung cancer[J].Critical Reviews in Oncology/Hematology,2004.119-133.
3Vanhoefer U,Harstrick A,Achterrath W. Irinotecan in the treatment of colorectal cancer:clinical overview[J].Journal of Clinical Oncology,2001,(05):1501-1518.
9Kelly K, Pan Z, Wood ME, et al. A phase Ⅰ study of paclitaxel, etoposlde, and cisplatin in extensive stage small cell lung cancer[J]. Clin Cancer Res, 1999, 5(11) :3419 -3424.
10Simon M, Argiris A, Murren JR. Progress in the therapy of small Cell lung cancer[J].Crit Rev Oncol Hematol, 2004, 49 (2) : 119 - 133.
4Yu Y, Zhang C, L~u L,et al. Hepatic arterial administration of gin- senoside Rg3 and transcatheter arterial embolization for the treat- ment of VX2 liver carcinomas [J]. Exp Ther Med, 2013,5 ( 3 ) : 761-766.
5Zhang YH,Li HD ,Li B,et al. Ginsenoside Rg3 induces DNA dam- age in human osteosarcoma cells and reduces MNNG-induced DNA damage and apoptosis in normal human cells [ J ]. Oncol Rep, 2014,31 (2) :919-925.
6Kim JW, Jung SY, Kwon YH, et al. Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial pro- genitor ceUs[ J]. Cancer Biol Ther,2012,13(7) :504-515.
